Would an unfavorable molecular subtype cause you to proceed with ALNDx after a positive SLNBx?

In a patient with a positive SLNBx, would triple negative or Her2+ status affect your decision on whether or not to proceed with a full ALNDx?

Answer from: Radiation Oncologist at Academic Institution

I dont think we have data to suggest ALND is required in unfavorable subtypes with positive SLN if meeting up front criteria of Z011/AMAROS. Roughly 15% of Z011 were ER- and 300 of the roughly 1400 in AMAROS did not receive endocrine therapy so likely there were some unfavorable in these studies.&nb...

Comments

Radiation Oncologist at Varian Medical Systems/Allegheny health network
Here is our data on patients underrepresented in Z...

Please select the option that best describes you:

Would an unfavorable molecular subtype cause you to proceed with ALNDx after a positive SLNBx?

Related Questions